TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03927339

Intervention type: DIAGNOSTIC_TEST
Intervention: pre and post excercise group
Description: Treadmill Training Protocol~Each eligible participant in the patients group was then prospectively assigned to undergo exercise session of full-body-free weight treadmill training. Once the participants were prepped, they performed stretching for 5 min and slow walking for 3 min as a warm-up exercise before starting the training. Stretch was carried out similarly to all the subjects to quadriceps femoris and the hamstring. In the warm-up time period , it was enforced for 3 min at the speed of1 km/h. Then patients began the walking trials and walked at 1 to 1.34 m/s on an electric car treadmill (JACO fitness: JACO-212C).
Study: NCT03462173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yimitasvir
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yimitasvir
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yimitasvir
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yimitasvir
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yimitasvir
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yimitasvir
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yimitasvir
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule
Study: NCT04512703

Intervention type: DEVICE
Intervention: µCor
Description: Sensor Monitor for arrhythmia and other bio-metric markers

Intervention type: DEVICE
Intervention: µCor
Description: Sensor Monitor for arrhythmia and other bio-metric markers
Study: NCT03856489

Intervention type: OTHER
Intervention: Richards-Campbell Sleeping Questionnaire (RCSQ)
Description: This five-item visual analogue scale was designed as an outcome measure for assessing the perception of sleep in critically ill patients. The scale evaluates perceptions of depth of sleep, sleep onset latency, number of awakenings, time spent awake, and overall sleep quality.

Intervention type: OTHER
Intervention: Richards-Campbell Sleeping Questionnaire (RCSQ)
Description: This five-item visual analogue scale was designed as an outcome measure for assessing the perception of sleep in critically ill patients. The scale evaluates perceptions of depth of sleep, sleep onset latency, number of awakenings, time spent awake, and overall sleep quality.
Study: NCT00058253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT03080935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
Study: NCT02577640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy bread
Description: Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (\~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy bread
Description: Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (\~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
Study: NCT02295644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Sonicator 740
Description: Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Sonicator 740
Description: Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Sonicator 740
Description: Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Sonicator 740
Description: Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
Study: NCT00838071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Specific intravenous anti-hepatitis B immunoglobulin
Description: Monthly doses of 5000 IU administered intravenously during 6 consecutive months
Study: NCT00943345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indometacin
Description: * capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).

Intervention type: DRUG
Group type: OTHER
Intervention: indometacin
Description: * capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).

Intervention type: DRUG
Group type: OTHER
Intervention: indometacin
Description: * capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).

Intervention type: DRUG
Group type: OTHER
Intervention: indometacin
Description: * capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).
Study: NCT01692119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular, pharmacy based intervention
Description: Regular, pharmacy-based intervention conducted in cooperation with the treating physician:~* Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.~* Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician.
Study: NCT03585270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Clazosentan will be administered as a continuous intravenous infusion at the dose of 15 mg/hour for up to 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
Study: NCT03472053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006 plus standard of care
Description: BIO-11006 is administered 125mg BID plus standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
Study: NCT00569101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg \~0.02 mg/kg + prednisolone tapering
Study: NCT01717222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Lignocaine
Description: Patients will receive 100 ml of 0.2% lignocaine
Study: NCT04445532

Intervention type: OTHER
Intervention: Gene expression analysis
Description: Gene expression analysis

Intervention type: OTHER
Intervention: Gene expression analysis
Description: Gene expression analysis

Intervention type: OTHER
Intervention: Genomic analysis
Description: Genomic analysis

Intervention type: OTHER
Intervention: Genomic analysis
Description: Genomic analysis

Intervention type: OTHER
Intervention: Protein expression analysis
Description: Protein expression analysis

Intervention type: OTHER
Intervention: Protein expression analysis
Description: Protein expression analysis

Intervention type: OTHER
Intervention: Proteomic profiling
Description: Proteomic profiling

Intervention type: OTHER
Intervention: Proteomic profiling
Description: Proteomic profiling

Intervention type: OTHER
Intervention: Polymerase chain reaction
Description: Polymerase chain reaction

Intervention type: OTHER
Intervention: Polymerase chain reaction
Description: Polymerase chain reaction

Intervention type: OTHER
Intervention: Mass spectrometry
Description: Mass spectrometry

Intervention type: OTHER
Intervention: Mass spectrometry
Description: Mass spectrometry

Intervention type: OTHER
Intervention: Immunohistochemistry
Description: Immunohistochemistry

Intervention type: OTHER
Intervention: Immunohistochemistry
Description: Immunohistochemistry

Intervention type: OTHER
Intervention: Metabolomics profiling
Description: Metabolomics profiling

Intervention type: OTHER
Intervention: Metabolomics profiling
Description: Metabolomics profiling

Intervention type: OTHER
Intervention: Methylation and epigenetic analysis
Description: Methylation and epigenetic analysis

Intervention type: OTHER
Intervention: Methylation and epigenetic analysis
Description: Methylation and epigenetic analysis

Intervention type: OTHER
Intervention: Liquid biopsy analysis
Description: Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis

Intervention type: OTHER
Intervention: Liquid biopsy analysis
Description: Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis

Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: Laboratory biomarker analysis (such as AFP, CA19-9, CEA)

Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: Laboratory biomarker analysis (such as AFP, CA19-9, CEA)
Study: NCT04107168

Intervention type: DRUG
Intervention: Nivolumab
Description: A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

Intervention type: DRUG
Intervention: Nivolumab
Description: A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

Intervention type: DRUG
Intervention: Nivolumab
Description: A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

Intervention type: DRUG
Intervention: Nivolumab
Description: A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

Intervention type: DRUG
Intervention: Nivolumab
Description: A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

Intervention type: DRUG
Intervention: Nivolumab
Description: A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

Intervention type: DRUG
Intervention: Nivolumab
Description: A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

Intervention type: DRUG
Intervention: Pembrolizumab
Description: A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
Study: NCT01717222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lignocaine
Description: Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
Study: NCT02756910

Intervention type: DEVICE
Intervention: iThermonitor (WT701)
Description: Continuously monitor the axillary temperature during surgery
Study: NCT04107168

Intervention type: DRUG
Intervention: Pembrolizumab
Description: A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.

Intervention type: DRUG
Intervention: Ipilimumab
Description: A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).

Intervention type: DRUG
Intervention: Ipilimumab
Description: A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).

Intervention type: DRUG
Intervention: Durvalumab
Description: A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).

Intervention type: DRUG
Intervention: Durvalumab
Description: A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).

Intervention type: DRUG
Intervention: Tremelimumab
Description: A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).

Intervention type: DRUG
Intervention: Atezolizumab
Description: A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).

Intervention type: DRUG
Intervention: Atezolizumab
Description: A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).

Intervention type: DRUG
Intervention: Bevacizumab
Description: A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
Study: NCT02093949

Intervention type: PROCEDURE
Intervention: Routine substrate ablation without pulmonary vein Isolation

Intervention type: PROCEDURE
Intervention: Routine conventional ablation with pulmonary vein Isolation
Study: NCT03475654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted rehabilitation
Description: The Jintronix software platform, coupled with the Microsoft Kinect for movement capture, contains individualized exercise modules to increase ROM, endurance and strength. Within this PRCT, online monitoring of activity and actigraphy measurements through a wearable device and completion of an online diary will provide enhanced monitoring of home activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge.
Study: NCT03914001

Intervention type: DEVICE
Group type: OTHER
Intervention: mpMRI
Description: all eligible patients will undergo mpMRI 4 weks after initial TURBT

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Second look TURBT
Description: after mpMRI all patients will subjected to second look TURBT
Study: NCT01202097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Study: NCT04035278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengusiil
Description: Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
Study: NCT03126669

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen
Description: Breathing 100% oxygen at 2ATA in the hyperbaric chamber

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric chamber, normal air
Description: Hyperbaric chamber with normal air
Study: NCT01953705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 PUFA
Description: fish oil concentrate standardized to long chain n-3 PUFA content

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02048475

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: desflurane
Description: changing concentration
Study: NCT02908295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal Misoprostol
Description: Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
Study: NCT02570204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-assessment
Description: Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
Study: NCT00022659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03167242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
Study: NCT03889704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnistim® FX²
Description: The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
Study: NCT01757197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toclizumab
Description: 8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
Study: NCT04439162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrograde cardioplegia protection
Description: antegrade-retrograde cardioplegia
Study: NCT04365023

Intervention type: DRUG
Intervention: platinum chemotherapy
Description: First line platinum chemotherapy
Study: NCT03167242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
Study: NCT02569593

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron supplements, more specific Ferrodyn and Vista Ferrum
Description: Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
Study: NCT01603901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regulated Negative Pressure-Assisted Wound Therapy Device
Description: Negative pressure will be applied in the usual way that is normally applied in our Medical Center
Study: NCT05483738

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinical assessment, blood samples, bone marrow and bone biopsy
Description: Assessment of blood samples, bone marrow and bone biopsy
Study: NCT00436852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00823576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.